83 results
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
undertaking of such Purchaser to the Israel Innovation Authority (the “IIA”) in customary form (the “IIA Undertaking”).
2.3 Closing Conditions
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
, through grants that we received from the Israel Innovation Authority, or the IIA (formerly the Office of the Chief Scientist of Israel’s Ministry … therefore must comply with the requirements of the Israeli Encouragement of Industrial Research, Development and Technological Innovation Law, 1984
F-3
BLRX
Bioline Rx Ltd
29 Dec 23
Shelf registration (foreign)
4:15pm
accounting firm.
As of the date of this prospectus supplement, we received approximately $22.0 million in funding from the Israel Innovation Authority
6-K
EX-99
BLRX
Bioline Rx Ltd
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
from the Israel Innovation Authority, or IIA, payments received under out-licensing arrangements, and interest earned on investments. We expect
6-K
EX-99
ax6ea5cenls7ifkz
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
k2vyt1rcvpdpltrdwsw5
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
3kdou
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
vx9 upjjov
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
8er341xee24lc8y6jsej
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
7y5745f
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
gp05k k05
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
hxl07ngbi29d
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
hxg2z hu9y
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
ptm7ys5 on1a38ddm
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
39u m0tjclqfiloih
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
9c2r f30q
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-99
7vfpcivze
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
424B5
is1c1kl fo75lcd2
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
2pilxrfs2rkd7ldc1a
15 Sep 22
Current report (foreign)
8:39am